Phreesia Inc - PHR STOCK NEWS

Phreesia, Inc. (PHR) reports strong financial results for Q4 and FY 2024, with revenue up 27% year-over-year. Despite a net loss, the company shows growth in AHSCs and total revenue. The outlook for FY 2025 indicates continued growth and improved Adjusted EBITDA.

Phreesia's Chief Clinical Officer, Dr. Hilary Hatch, selected for NQF's 2024-2025 Leadership Consortium, showcasing dedication to healthcare quality and patient-centered care. Dr. Hatch leads clinical programs, research partnerships, and patient engagement efforts at Phreesia, emphasizing the importance of patient activation in improving health outcomes.

Phreesia's breast cancer-prevention campaign resulted in 32% of patients requesting a screening, showcasing the positive impact of their platform on increasing cancer screening rates.

Phreesia, Inc. (PHR) will release its fiscal fourth quarter 2024 financial results on March 14, 2024, followed by a conference call to discuss the results. The company's quarterly stakeholder letter and press release will be available on its investor website. Participants can join the conference call via phone or webcast, with a replay available for on-demand listening.

Phreesia has joined the National Adult and Influenza Immunization Summit’s Call to Action for Adult Immunizations campaign to improve adult vaccination rates. The campaign aims to encourage healthcare providers to take action to protect adults from preventable illness, disability, and death. More than three in four adults are missing routinely recommended vaccines, and low vaccination rates have worsened due to preventive care put on hold during the COVID-19 pandemic. Phreesia's vaccine management tools support healthcare organizations by collecting critical information, engaging patients, and giving them the resources they need to make informed decisions.

Phreesia's Vice President of Client Solutions, Audrey Gato, has been named to The Software Report’s list of the Top 50 Women Leaders in SaaS of 2023, marking the sixth consecutive year a female leader from Phreesia has been recognized. Gato's role involves overseeing client implementation and account management for Phreesia’s payer and managed service offerings, as well as leading client efforts around clinical programs such as the Kidney Care Choices (KCC) Model and Merit-based Incentive Payment System (MIPS). The Software Report highlighted the diverse leadership roles of the award recipients, emphasizing their adept leadership within the SaaS industry. Gato expressed her honor in being recognized and emphasized Phreesia's commitment to introducing new initiatives and products to serve clients and the healthcare industry.

Phreesia (PHR) has been recognized by PM360 for its innovative medication adherence solution, Post-Script Engagement, being named to the list of 2023 Most Innovative Marketing Technologies or Services. The offering was selected as one of 56 overall honorees, and one of just 8 technologies or services to be recognized for marketing innovation. Post-Script Engagement provides patients with resources to adhere to their medication as soon as their prescription is written, delivering curated content in a secure manner. The engagement also includes a survey to measure patients' likelihood to fill their prescription, providing insights to help doctors tailor their interactions with patients to address their unique adherence challenges. Phreesia's VP of Product Management, Kristin Roberts, expressed pride in offering Post-Script Engagement as part of a medication adherence product suite that supports patients, providers, and life sciences partners.

Phreesia, Inc. (NYSE: PHR) announced its fiscal third-quarter results, reporting total revenue of $91.6 million, a 25% increase from the previous year. The net loss was $31.9 million, down from $40.2 million in the prior year. The company acquired ConnectOnCall.com, LLC for $13.9 million and replaced its credit facility with a new 5-year $50 million senior secured asset-based revolving credit facility with Capital One, N.A. Phreesia is maintaining its revenue outlook for fiscal year 2024 at $353 million to $356 million, with a year-over-year growth of 26% to 27%. The company is introducing its revenue outlook for fiscal 2025, expecting revenue to be in the range of $424 million to $434 million.

Phreesia (PHR) is pleased to announce that the Centers for Medicare and Medicaid Services (CMS) has included the Patient Activation Measure Performance Measure (PAM-PM) in its Merit-Based Incentive Payment System (MIPS), as well as in 15 specialty-specific measure sets and five MIPS Value Pathways (MVPs), subsets of measures for specific conditions. The PAM measures a patient’s knowledge, skills, and confidence to self-manage their health. The measure steward of the PAM is Insignia Health, a wholly owned subsidiary of Phreesia. The PAM is used to support patients in taking a more active role in their care, driving better outcomes, especially for patients who need it most. The PAM has been included as a high priority outcome measure in the 2024 Medicare Physician Fee Schedule published by CMS. This move demonstrates CMS's commitment to person-centered care and health equity. The PAM has been developed nearly two decades ago and has been backed by a large body of research, with more than 800 peer-reviewed studies demonstrating its unique value. Beginning in 2024, MIPS-participating providers can report on gains in patient activation as a new quality measure, showcasing the importance of the PAM in understanding patients, allocating resources efficiently, and getting patients the support they need.